Abstract: Provided is a disclosure for embodiments for a brush with communication capabilities, which is configured to clean a surface of, for example, a semiconductor wafer, as well as an offline brush conditioning system and a CMP system that can communicate with the brush.

Abstract: Provided is a disclosure for embodiments for a brush with communication capabilities, which is configured to clean a surface of, for example, a semiconductor wafer, as well as an offline brush conditioning system and a CMP system that can communicate with the brush.

Abstract: Provided is disclosure for embodiments providing delivery of chemicals for conditioning a brush offline, where the brush is not coupled to a machine that makes use of the brush to clean a surface of an object.

Abstract: Provided is a disclosure for embodiments that perform effluent monitoring for brush conditioning, where the monitored data may be fed back for use in the conditioning.

Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

Abstract: A curtain wall panel includes frame with a first frame member defining a channel, a cover configured to extend over the first frame member, a spacer formed of a thermally insulating material, the spacer including a first end, a body, and a second end, the first end being configured to be secured in the channel of the first frame member in a cammed interference fit by rotating a body of the spacer, and the second end being configured to form a cammed interference fit with the cover. An insert is supported from the first frame member by the spacer with the cover fit onto the spacer to capture and secure the insert relative to the frame.

Abstract: A propulsion system for an aircraft includes an engine (e.g., piston engine, or turbine) having an axis made to be nonparallel with the longitudinal axis of the aircraft. This is enabled using an electrical, hydraulic, or other system to transfer energy generated by the engine (e.g., via electrical wiring, fluid conduits, etc.) to remotely power a motor used to drive a thrust-creating device (e.g., propeller or ducted fan). That the engine is able to be freely oriented allows for it being positioned without regard to any mechanical restraints existing in conventional arrangements.

Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

Abstract: A curtain wall panel includes frame with a first frame member defining a channel, a cover configured to extend over the first frame member, a spacer formed of a thermally insulating material, the spacer including a first end, a body, and a second end, the first end being configured to be secured in the channel of the first frame member in a cammed interference fit by rotating a body of the spacer, and the second end being configured to form a cammed interference fit with the cover. An insert is supported from the first frame member by the spacer with the cover fit onto the spacer to capture and secure the insert relative to the frame.

Abstract: Small structures are formed by applying to a substrate a structural material and a layer of a sacrificial material having a lower surface energy than the structural material, to form an intermediate product. The substrate is then heated to a temperature at which the sacrificial material evaporates or sublimes and the structural material is mobilized. The sacrificial material is permitted to evaporate or sublime, an area of the substrate covered by the sacrificial material to diminish, and the structural material to agglomerate on the remaining sacrificial material to form a structure.

Abstract: A curtain wall panel includes frame with a first frame member defining a channel, a cover configured to extend over the first frame member, a spacer formed of a thermally insulating material, the spacer including a first end, a body, and a second end, the first end being configured to be secured in the channel of the first frame member in a cammed interference fit by rotating a body of the spacer, and the second end being configured to form a cammed interference fit with the cover. An insert is supported from the first frame member by the spacer with the cover fit onto the spacer to capture and secure the insert relative to the frame.

Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

Abstract: A tolerance ring can include a generally cylindrical body having a sidewall. The sidewall can include a first unformed section and a gap in the first unformed section. The gap can extend along an entire length of the body to establish a split in the body. The sidewall can also include a second unformed section opposite the first unformed section, a first wave bank flanking the first unformed section with the gap, and a second wave bank flanking the first unformed section with the gap. The wave banks can be equally spaced around a circumference of the body of the tolerance ring and the body of the tolerance ring can be symmetrical about a center axis that extends from a center of the tolerance ring and bisects the gap in the first unformed section.

Abstract: A torque limiting tolerance ring that is configured to be installed between an inner component and an outer component is disclosed. The torque limiting tolerance ring can include a generally cylindrical body that can have a sidewall. The sidewall can include an unformed section and a plurality of projections can extend from the unformed section of the sidewall. The projections can be configured to engage the inner component or the outer component. During use, the torque limiting tolerance ring can move from an engaged configuration, in which the inner component is statically coupled to the outer component, to a disengaged configuration, in which the inner component is disengaged from the outer component.

Abstract: A method of producing a conformal cooling passage in a part-producing mold, and a mold provided with such a conformal cooling passage. The conformal cooling passage is produced by creating a number of open channels in a molding surface of a mold of interest, the channels substantially conforming to the contour of the molding surface. A bridging weld formed from a plurality of connected weld beads is generated in each channel so as to span and seal each channel while enclosing an open passage in the bottom thereof. The remainder of each channel above its bridging weld is filled, such as by welding, and the area of each channel is subsequently shaped to conform with the contours of the molding surface surrounding that channel. A sub-surface conformal cooling passage is thus formed in the mold.

Abstract: A tolerance ring can include a generally cylindrical body that can include a side wall. The sidewall can define a top and a bottom. Further, the sidewall can include a plurality of wave structures that can extend from the sidewall, a plurality of unformed sections, and a gap that can extend along the entire length of the body. Each unformed section can be located between a pair of adjacent wave structures. Further, the gap can establish a split in the body. The tolerance ring can also include at least one hole intersecting at least one of the wave structures to establish a perforated wave structure.

Abstract: A tolerance ring can include a generally cylindrical body having a sidewall. The sidewall can include a plurality of wave structures extending from the sidewall at regular intervals around the body, a first unformed section between a first pair of adjacent wave structures, and a second unformed section between a second pair of adjacent wave structures. The gap can extend along an entire length, L, of the body to establish a split in the body. The second unformed section can include a slot therein. The slot can have a length, LS, and LS?80% L.

Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

Abstract: A curtain wall panel includes frame with a first frame member defining a channel, a cover configured to extend over the first frame member, a spacer formed of a thermally insulating material, the spacer including a first end, a body, and a second end, the first end being configured to be secured in the channel of the first frame member in a cammed interference fit by rotating a body of the spacer, and the second end being configured to form a cammed interference fit with the cover. An insert is supported from the first frame member by the spacer with the cover fit onto the spacer to capture and secure the insert relative to the frame.

Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.